138 related articles for article (PubMed ID: 25166437)
1. Analysis of free serum light chains in patients suffering from multiple myeloma complicated by light-chain amyloidosis.
Usnarska-Zubkiewicz L; Hołojda J; Dębski J; Zubkiewicz-Zarębska A; Zagocka E; Kuliczkowski K
Adv Clin Exp Med; 2014; 23(4):531-8. PubMed ID: 25166437
[TBL] [Abstract][Full Text] [Related]
2. IgD multiple myeloma: Clinical, biological features and prognostic value of the serum free light chain assay.
Djidjik R; Lounici Y; Chergeulaïne K; Berkouk Y; Mouhoub S; Chaib S; Belhani M; Ghaffor M
Pathol Biol (Paris); 2015 Sep; 63(4-5):210-4. PubMed ID: 26294067
[TBL] [Abstract][Full Text] [Related]
3. [The clinical significance of serum free light chain in primary systemic amyloidosis].
Zhai YP; Song P; Li F; Liu HN; Yu YP; Zhou XG; Shi P; An ZM; Zhou X; Zhang CN
Zhonghua Nei Ke Za Zhi; 2011 May; 50(5):404-7. PubMed ID: 21624224
[TBL] [Abstract][Full Text] [Related]
4. Quantitation of serum free light chains in combination with protein electrophoresis and clinical information for diagnosing multiple myeloma in a general hospital population.
Piehler AP; Gulbrandsen N; Kierulf P; Urdal P
Clin Chem; 2008 Nov; 54(11):1823-30. PubMed ID: 18801937
[TBL] [Abstract][Full Text] [Related]
5. Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio.
Prokaeva T; Spencer B; Sun F; O'Hara RM; Seldin DC; Connors LH; Sanchorawala V
Amyloid; 2016 Dec; 23(4):214-220. PubMed ID: 27677679
[TBL] [Abstract][Full Text] [Related]
6. [Bilateral pleurisy revealing a myelome with free light chains complicated with an osseous amylose].
El Boukhrissi F; Balouch L; Hachimi MA; Hommadi A; Idrissi MM; Bamou Y
Ann Biol Clin (Paris); 2011; 69(5):593-6. PubMed ID: 22008141
[TBL] [Abstract][Full Text] [Related]
7. Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free light chain test.
Heaney JLJ; Campbell JP; Yadav P; Griffin AE; Shemar M; Pinney JH; Drayson MT
BMC Nephrol; 2017 Jul; 18(1):247. PubMed ID: 28728609
[TBL] [Abstract][Full Text] [Related]
8. Serum free light chain response after 2 courses of induction chemotherapy predicts prognosis in myeloma patients.
Yağcı M; Karakaya F; Suyanı E; Haznedar R
Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):98-102. PubMed ID: 25441109
[TBL] [Abstract][Full Text] [Related]
9. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis.
Kourelis TV; Kumar SK; Gertz MA; Lacy MQ; Buadi FK; Hayman SR; Zeldenrust S; Leung N; Kyle RA; Russell S; Dingli D; Lust JA; Lin Y; Kapoor P; Rajkumar SV; McCurdy A; Dispenzieri A
J Clin Oncol; 2013 Dec; 31(34):4319-24. PubMed ID: 24145344
[TBL] [Abstract][Full Text] [Related]
10. The occurrence of Al amyloidosis (light-chain amyloidosis) in patients with multiple myeloma in Lower Silesia Region, Poland.
Usnarska-Zubkiewicz L; Hołojda J; Jeleń M; Zubkiewicz-Zarębska A; Dębski J; Kuliczkowski K
Adv Clin Exp Med; 2014; 23(2):235-44. PubMed ID: 24913114
[TBL] [Abstract][Full Text] [Related]
11. Light-chain removal by plasmapheresis in myeloma-associated renal failure.
Cserti C; Haspel R; Stowell C; Dzik W
Transfusion; 2007 Mar; 47(3):511-4. PubMed ID: 17319833
[TBL] [Abstract][Full Text] [Related]
12. [Clinical Significance of Serum Free Light Chain and Its κ/λ Ratio in Patients with Multiple Myeloma].
Zhao D; Jiang JQ; Lin L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1173-1178. PubMed ID: 31418375
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis.
Matsuda M; Yamada T; Gono T; Shimojima Y; Ishii W; Fushimi T; Sakashita K; Koike K; Ikeda S
Intern Med; 2005 May; 44(5):428-33. PubMed ID: 15942088
[TBL] [Abstract][Full Text] [Related]
14. [A case of amyloidosis complicated by IgU/lambda/-myeloma multiplex].
Husz S; Török L; Kovács L; Szabó E; Simon N
Z Hautkr; 1979 Jul; 54(13):585-9. PubMed ID: 113946
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of the relationship of heavy/light chain pairs of immunoglobulin (Hevylite) to the results of gel electrophoresis and nefelometric examination of serum proteins at the time of multiple myeloma diagnosis].
Ščudla V; Lochman P; Pika T; Zapletalová J; Minařík J; Bačovský J
Cas Lek Cesk; 2015; 154(6):292-302. PubMed ID: 26750626
[TBL] [Abstract][Full Text] [Related]
16. Isolation and biochemical characterization of plasma monoclonal free light chains in amyloidosis and multiple myeloma: a pilot study of intact and truncated forms of light chains and their charge properties.
Kaplan B; Ramirez-Alvarado M; Dispenzieri A; Zeldenrust SR; Leung N; Livneh A; Gallo G
Clin Chem Lab Med; 2008; 46(3):335-41. PubMed ID: 18254719
[TBL] [Abstract][Full Text] [Related]
17. Association light chain deposition disease (LCDD) and amyloidosis. One case.
Hofmann-Guilaine C; Nochy D; Jacquot C; Tricottet V; Bariety J; Camilleri JP
Pathol Res Pract; 1985 Aug; 180(2):214-9. PubMed ID: 3932985
[TBL] [Abstract][Full Text] [Related]
18. The association of serum-free light-chain levels with markers of renal function.
Erdem BK; Davran F; Yilmaz VT; Çetinkaya R; Akbas H
Ren Fail; 2015 Jul; 37(6):1057-60. PubMed ID: 26056734
[TBL] [Abstract][Full Text] [Related]
19. Frequency of light chain deposition nephropathy relative to renal amyloidosis and Bence Jones cast nephropathy in a necropsy study of patients with myeloma.
Iványi B
Arch Pathol Lab Med; 1990 Sep; 114(9):986-7. PubMed ID: 2117910
[TBL] [Abstract][Full Text] [Related]
20. Preferential expression of human lambda-light-chain variable-region subgroups in multiple myeloma, AL amyloidosis, and Waldenström's macroglobulinemia.
Ozaki S; Abe M; Wolfenbarger D; Weiss DT; Solomon A
Clin Immunol Immunopathol; 1994 May; 71(2):183-9. PubMed ID: 8181187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
